CTS faced a challenging Q3, with the market reacting negatively to its results despite revenue growth outpacing Wall Street’s expectations. Management attributed the underperformance to a mix of end market trends, including strong gains in medical, aerospace and defense, and industrial segments, offset by weaker transportation demand. CEO Kieran O’Sullivan highlighted that, “diversified sales for the quarter were 59% of overall company revenue,” reflecting an ongoing strategic focus. Margins were pressured by an adverse tax impact and a reserve increase related to an environmental claim.

Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From CTS’s Q3 Earnings Call

• John Franzreb (Sidoti & Company) questioned the rationale behind raising revenue guidance while lowering EPS guidance. CEO Kieran O’Sullivan cited top-line momentum in diversified markets but emphasized tax impacts on the bottom line, while CFO Ashish Agrawal pointed to ongoing adverse tax legislation effects.
• Hendi Susanto (Gabelli Funds) pressed for clarity on whether the adverse tax rate would improve in 2026. Agrawal responded that while some efficiency measures are possible, tax impacts would likely persist, with a forecasted rate in the low 20% range.
• Susanto (Gabelli Funds) also asked about the inventory situation in transportation. O’Sullivan said light vehicle inventory levels appear normal, but commercial vehicle demand remains a concern, warranting close monitoring.
• Franzreb (Sidoti & Company) sought insight on gross margin contributions by end market. Agrawal explained margins are more product-line driven, with single crystal and frequency products carrying higher margins than other lines, rather than being strictly end-market dependent.
• Susanto (Gabelli Funds) further questioned the rise in SG&A expenses. Agrawal attributed most of the increase to a $4.2 million EPA-related reserve and higher equity-based compensation reflecting performance adjustments.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will watch (1) whether medical therapeutics and aerospace and defense bookings continue their current momentum, (2) signs of stabilization or recovery in transportation end markets, especially commercial vehicles, and (3) the ongoing impact of U.S. tax legislation and environmental reserves on margins. Progress on SyQwest’s contract pipeline and adoption of new vehicle electronics platforms will also be critical signposts.

CTS currently trades at $41.64, down from $42.41 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

The Best Stocks for High-Quality Investors

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.